Fractyl Health, Inc. (NASDAQ:GUTS) Short Interest Down 34.7% in April

Key Points

• Short interest down 34.7% — short interest fell to 3,889,527 shares as of April 15, with a short-interest ratio of 3.0 days and about 3.3% of the float shorted.
• Earnings beat but outlook mixed — the company reported $0.15 EPS for the quarter, topping the -$0.19 consensus, yet analysts still forecast -0.67 EPS for the fiscal year and maintain mixed ratings (average "Hold" with a $5.40 price target).
• Low share price and modest market cap — shares traded around $0.66 (mid-day) with a market cap of ~$104.1M, a 12‑month range of $0.38–$3.03, and a 50‑day SMA ($0.49) below the 200‑day SMA ($1.17), indicating downward momentum.

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totaling 3,889,527 shares, a decrease of 34.7% from the March 31st total of 5,957,044 shares. Based on an average daily volume of 1,281,990 shares, the short-interest ratio is currently 3.0 days. Currently, 3.3% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Jane Street Group LLC bought a new position in Fractyl Health during the 2nd quarter worth $31,000. FNY Investment Advisers LLC bought a new position in Fractyl Health during the 3rd quarter worth $31,000. Jump Financial LLC bought a new position in Fractyl Health during the 4th quarter worth $57,000. Scientech Research LLC bought a new position in Fractyl Health during the 3rd quarter worth $49,000. Finally, Prelude Capital Management LLC bought a new position in Fractyl Health during the 3rd quarter worth $55,000.

Fractyl Health Price Performance

Shares of NASDAQ GUTS traded up $0.00 during mid-day trading on Tuesday, hitting $0.66. 1,126,201 shares of the stock traded hands, compared to its average volume of 1,496,904. The company has a debt-to-equity ratio of 3.23, a current ratio of 4.78 and a quick ratio of 4.78. Fractyl Health has a twelve month low of $0.38 and a twelve month high of $3.03. The company has a market cap of $104.12 million, a PE ratio of -0.36 and a beta of 1.20. The firm has a 50 day simple moving average of $0.49 and a two-hundred day simple moving average of $1.17.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last announced its earnings results on Tuesday, March 24th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.34. As a group, equities research analysts forecast that Fractyl Health will post -0.67 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on GUTS. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Fractyl Health in a report on Monday, December 29th. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 target price on shares of Fractyl Health in a report on Friday. Morgan Stanley downgraded Fractyl Health from an "overweight" rating to an "equal weight" rating and reduced their target price for the company from $8.00 to $2.00 in a report on Thursday, January 29th. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $8.00 price target on shares of Fractyl Health in a research note on Thursday, March 26th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $5.40.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company's lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.